Abstract Accumulation of smooth muscle cells (SMC) results in neointima formation in injured vessels. Two graft models consisting of vein and artery grafts were created by anastomosing common carotid arteries to donor vessels. To identify the origin of the neointima cells from anastomosed arteries, we use Wnt1-Cre/reporter mice to label and track SMCs in the common carotid artery. The contribution of SMCs in the neighboring arteries to neointima formation was studied. On evaluating the artery grafts after 1 month, [90 % of the labeled neointima cells were found to have originated from the anastomosing host arteries. Most of the neointima cells were also smooth muscle a-actin positive (SMA-a ? ) and expressed the smooth muscle myosin heavy chain (SMMHC), the SMC terminal differentiation marker. In vein grafts, about 60 % SMA-a-positive cells were from anastomosing arteries. Bone marrow cells did not contribute to neointima SMCs in vein grafts, but did co-stain with markers of inflammatory cells. Wnt1 expression was not detected in the neointima cells in the vein or artery grafts, or the injured femoral arteries. Neointima SMCs showed the synthetic phenotype and were positively labeled with BrdU in vitro and in vivo. Treatment with the IGF-1 receptor inhibitor suppressed SMC proliferation and neointima formation in vein grafts. Our results indicate that SMCs from the neighboring artery are predominantly present in the neointima formed in both vein and artery grafts and that Wnt1-Cre mice can be used to explore the role of SMCs originating from neighboring vessels in vascular remodeling.
Introduction
SMC accumulation and neointima formation are major contributors to vascular remodeling that can result in graft failure after angioplasty or coronary artery bypass surgery. In fact, formation of neointima is the main cause of failure in about 40 % of autologous vein grafts employed in coronary artery bypass surgery [11, 25] . Multiple types of cells have been implicated in neointima formation [3, 37] , including the circulating fibrocytes, bone marrow-derived circulating progenitor cells [33, 34] , and cells from endothelial-mesenchymal transition [1] . Besides distal source of cells, local cell types (including resident SMC progenitor cells, adventitial cells, or mature SMCs) can give rise to SMCs in the neointima [2, 13, 14, 16] .
The problem with identifying the origin of cells that constitute a neointima is the absence of animal models that can specifically label these ''SMC precursors''. Therefore, while transgenic mice overexpressing LacZ or GFP are used frequently to study the origin of neointima cells in vascular grafts, the lack of a tissue specific labeling strategy does not allow clear identification of the source of cells from the donor to that of the recipient.
To overcome this shortcoming, we studied Wnt1-Cre transgenic mice to label and track neural crest cells and their derivatives. It is well established that during development, SMCs of the cardiac outflow tract (including the common carotid artery) are derived from Wnt1-expressing neural crest cells [20] while those in other vessels including the vena cava and the descending aorta are not [20, 36] . In adult mice, most of the Wnt1 expression can be found in neurons, and not in neural crest-derived SMCs of the common carotid artery [24] . Applying these features of Wnt1 expression, we have bred Wnt1-Cre with the Floxedreporter transgenic mice to generate offsprings in which the neural crest-derived SMCs in the common carotid artery (and cardiac outflow tract) are labeled permanently by the reporter genes, while SMCs in the other vessels remain unlabeled. We reasoned that after grafting an unlabeled vessel (vein or artery) onto the common carotid artery of Wnt1-Cre/reporter mice, the contribution of ''local'' neighboring SMCs to the neointima cells could be tracked and identified. SMCs of the common carotid arteries from the two transgenic mice, LacZ-Stop flox /Wnt1-Cre and RFP flox -GFP/Wnt1-Cre, expressing LacZ and GFP, respectively, were used for the current studies. Donor arteries or veins from wild-type (WT) mice were grafted onto the carotid artery of these reporter mice and the incorporation of labeled cells and BrdU proliferative cells in the neointima from the arterial or vein grafts were tracked and examined. We found that LacZ ? or GFP ? cells in the neointimas were co-stained with SMC specific markers, SMA-a and SMMHC, in the two graft models. Blocking SMC proliferation attenuates neointima formation in the vein graft. These results indicate that the migration and proliferation of SMCs from the neighboring arteries significantly contributes to neointima formation. 
Materials and methods

Mice
Antibodies and reagents
Antibodies against GFP (rabbit), SMA-a (rabbit), CD11b, SMMHC (rabbit) and Wnt1 were from Abcam (Cambridge, MA, USA); SMA-a-FITC (mouse), antibodies against b-actin, bromodeoxyuridine (BrdU), and picropodophyllotoxin (PPP), the IGF-1 receptor inhibitor were purchased from Sigma-Aldrich (St. Louis, MO, USA); the DsRed (rabbit) antibodies were from Rockland Inc (Danvers, MA, USA); antibodies against RFP (goat) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-GFP (mouse) antibodies were obtained from Invitrogen (Carlsbad, CA, USA). Anti-CD3 and neutrophil antibodies were purchased from eBioscience (San Diego, CA, USA). The anti-CD31 and -CD45 antibodies were from BD Pharmingen (San Jose, CA, USA). BrdU Labeling and Detection Kits were obtained from Roche (Indianapolis, IN, USA).
Vein graft procedure
All animal protocols were approved by IACUC. In brief, recipient mice were anesthetized with an intraperitoneal injection of xylazine and ketamine cocktail (8.8-mg/kg xylazine and 130-mg/kg ketamine). The right common carotid artery of a male mouse was mobilized and dissected. A cuff (*1.0 mm 9 *0.5-0.8 mm, length 9 diameter) was placed on both ends of the artery. The ends of the artery were everted over the cuff and ligated with a 8.0 silk suture. Vena cava from donor mice was grafted between the two ends of the carotid artery by ''sleeving'' the ends of the vein over the cuff; they were secured with 8.0 silk sutures. After 4 weeks, mice were perfused with 4 % paraformaldehyde (PFA) via the left ventricle for 10 min, the vein grafts were collected, and cryo or paraffin sections were prepared based on proposed experiments. The vessel wall thickness was measured by the NIS-Elements BR 3.0 program as area of the vessel minus that of the lumen. In experiments designed to detect the effects of IGF-1 receptor inhibitor on neointima formation in vein grafts, mice were treated with PPP (20 mg/kg) or drug-free solvent i.p. every 2 days for 3 weeks before the graft collection.
Artery graft procedure
The surgical procedure was similar to that for vein graft. The anesthetized donor mouse was perfused with saline, and the right common carotid artery was injured by wire (0.38 mm in diameter, Abbot Vascular Inc., Abbott Park, IL, USA) and placed in saline at room temperature. Recipient mice were anesthetized and the right common carotid artery of a male mouse was mobilized and dissected. A cuff was placed on both ends of the artery and the injured artery (*8 mm) from donor mice was grafted between the two ends of the carotid artery. After 4 weeks, mice were perfused with 4 % PFA via the left ventricle for 10 min, the artery grafts were collected, and cryo or paraffin sections were prepared based on proposed experiments for X-Gal or immunostaining.
BrdU experiments
BrdU was administered to the mice (i.p., 1.5 mg/day) for 7 days before graft collection. BrdU immunofluorescent staining was performed according to the manufacturer's instructions (BrdU Labeling and Detection Kit, Roche, Indianapolis, IN, USA).
Mouse femoral artery injury model
The mice were anesthetized as above. The femoral artery was isolated, the vein and connective tissues around the artery were carefully removed with microsurgery forceps (Dumont S.A., Switzerland). The exposed muscular branch artery was dilated by topical application of one drop of 1 % lidocaine hydrochloride. The injury model of the femoral artery was performed as described [31] with some modifications. Briefly, the end-blunted 31-gauge needle (0.26 mm in diameter) was inserted into the profunda femoris artery, pushed forward for *5-10 mm toward the iliac artery and left in place for 1 min, to dilate the artery. The blood flow was reconstituted after ligation of the profunda femoris branch. After 4 weeks, mice were perfused with 4 % PFA via the left ventricle for 10 min. The femoral artery was carefully excised, fixed in 4 % PFA for 24 h, and embedded in paraffin.
X-Gal staining 5-lm sections of grafts were washed in PBS for 10 min, incubated in blocking buffer (1 mM MgCl 2 , 0.01 % Nadeoxycholate, 0.02 % IGEPAL-CA630, and 5 mM EGTA in PBS) for 20 min at room temperature, and incubated in the X-Gal mixture (1 mM MgCl 2 , 0.01 % Na-deoxycholate, 0.02 % IGEPAL-CA630, 5 mM EGTA, 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 Á3H 2 O, and 1 lg X-Gal; all from Sigma-Aldrich) for 16 h at 37°C. Alternatively, cryo sections were incubated for 16 h with a commercially available b-Gal staining kit, specifically designed to minimize staining from endogenous b-Gal (Roche Diagnostics Corp).
Immunohistochemistry
For histological analysis, vein or artery grafts were perfused through the left ventricle as described [6] . Grafts were fixed with 4 % phosphate-buffered formaldehyde at 4°C for 24 h and processed as described [5] . Sections were blocked with 10 % goat serum (Vector Laboratories, Burlingame, CA, USA) for 30 min and then incubated with primary antibodies. After washing in 0.5 % Tween 20 in PBS (PBST), these sections were incubated with a biotinylated secondary antibody (Vector lab) at room temperature. Following a repeat washing with PBST, tissue sections were incubated with an Elite Ò ABC reagent (Vector Laboratories) followed by a peroxidase substrate kit (Vector Laboratories) according to the manufacturer's protocol. The sections were counterstained by hematoxylin. For double immunofluorescent staining of samples, fluorescent secondary antibodies were applied to sections; DAPI was used as a counter stain.
Pictures were recorded using a Nikon Eclipse 80i fluorescence microscope (Melville, NY, USA).
Bone marrow isolation and transplantation
Bone marrow (BM) transplantation was performed as described [6] . Briefly, mice were anesthetized with an intraperitoneal injection of xylazine and ketamine cocktail (8.8 mg/kg xylazine and 130 mg/kg ketamine). The BM donor mice were euthanized by cervical dislocation and cells were harvested by flushing their femurs and tibias. The transplant was created by injecting 5 9 10 6 bone marrow cells into the lateral tail vein of lethally irradiated (1,100 rads) mice recipients.
Statistical analysis
All data are presented as mean ± SEM. Comparison between groups was made using one-way ANOVA followed by pairwise comparisons with p value adjustment; p \ 0.05 was considered statistically significant.
Results
Wnt1-Cre mediates a conditional expression of the reporter genes in SMCs of the common carotid artery LacZ-Stop flox /Wnt1-Cre ? mice were generated to label Wnt1
? lineage cells. Staining for X-Gal was found to be positive only in the SMCs of the common carotid artery and was negative for cells of the endothelial layer (Fig. 1a) . Likewise, there was no LacZ activity in SMCs in the vena cava (Fig. 1a) . These observations were confirmed in RFP flox -GFP/Wnt1-Cre ? mice in which the expression of RFP was switched to GFP in SMCs of the common carotid artery (Fig. 1b) . There was no expression of GFP in ECs as well as the SMCs of the vena cava or the descending aorta (because these SMCs were not of neural crest origin) in RFP flox -GFP/Wnt1-Cre ? mice (Fig. 1b) . In Wnt1-Cre negative control mice, SMCs in carotid artery were RFP positive (Fig. 1b, left panel) . Because neurons express Wnt1 [9] , as expected, the vagus nerve was GFP ? in RFP flox -GFP/Wnt1-Cre ? mice (Fig. 1c) . These results indicate that Wnt1-Cre reporter mice can be used to specifically label the SMCs in the common carotid artery, and leave SMCs in other vessels unlabeled.
SMCs from a neighboring artery contribute to neointima formation in artery grafts When artery grafts were created in WT mice, there was a significant increase in the accumulation of SMA-a-positive cells in the neointima after 1 month, thus leading to a smaller lumen when compared with that in control arteries (Fig. 2a,  b) . To identify the origin of these neointima cells, artery (Fig. 2c, e) . These results suggest that X-Gal-positive cells found in the neointima were originated from the SMCs of the neighboring artery, because only SMCs in the host common carotid artery express LacZ. Conversely, when arteries from LacZ-Stop flox /Wnt1-Cre ? mice were grafted into LacZ-Stop flox /Wnt1-Cre -mice, most of the neointima cells did not exhibit X-Gal expression except for a few (Fig. 2d, e) . Furthermore, since all SMCs in the media layer were X-Gal positive, this suggested that donor artery SMCs survived during the experiment, but did not contribute to neointima formation (Fig. 2d) .
Arterial injury does not activate Wnt1 during neointima formation
We next tested whether Wnt1 begins to express during neointima formation, since such expression would stimulate Wnt1-Cre-mediated DNA recombination, which compromises the specificity to track the media SMCs from the neighboring artery. Immunostaining revealed no Wnt1-positive staining in artery grafts. However, the neointima cells expressed SMA-a and the SMMHC. The isotype IgG control did not show any specific staining for these markers (Fig. 3a) . To further examine whether Wnt1 is activated during neointima formation, we performed a femoral arterial injury model in Wnt1-Cre reporter mice. This model was chosen because SMCs in the femoral artery are not neural crest-derived and not pre-labeled in Wnt1-Cre reporter mice (Fig. 3c, e) . When the femoral artery was injured in RFP flox -GFP/Wnt1-Cre ? mice, the neointima formed after 1 month (Fig. 3b) . The SMA-a-positive cells accumulated in the injured femoral artery but not in the uninjured control artery and there were no GFP-positive cells in the neointima (Fig. 3c, right panel) . Only para-vessel nerves stained positively for GFP around the vessels (Fig. 3c) . Conversely, there was no Wnt1 expression in the neointima in the injured femoral artery (Fig. 3d, left panel) , while as a positive control, the femoral nerve was Wnt1 positive (Fig. 3d, right  panel) . In addition, the femoral arterial injury model was also performed in LacZ-Stop flox /Wnt1-Cre ? mice. Results obtained through X-Gal staining showed that only parafemoral arterial nerves were stained blue, as opposed to the smooth muscle layer (Fig. 3e, left panel) . Likewise, we found that the femoral arterial injury in LacZ-Stop flox /Wnt1-Cre ? mice yielded no X-Gal-positive cells in the neointima, though the femoral nerve (Fig. 3e, right panel) and some para-vessel nerves of the injured artery were X-Gal positive (Fig. 3e, red arrows marked cells in middle panel) . These results suggest that Wnt1 gene was not activated and expressed during arterial injury. 
Neighboring arterial SMCs contribute to neointima formation in vein grafts
Vein grafts were created in RFP flox -GFP/Wnt1-Cre ? mice with donor vena cava from WT mice. After 1 month, multiple layers of neointima cells in the vein grafts were SMA-a positive (Fig. 4a, b) . To detect whether Wnt1-Cre efficiently regulates GFP expression in the common carotid artery, the GFP was co-stained with SMMHC. As shown in Fig. 4c , all the SMCs were double positive for GFP/SMMHC and SMA-a/SMMHC in the common carotid artery in RFP flox -GFP/Wnt1-Cre ? mice, while the ECs were negatively stained (Fig. 4c, d ), indicating that the GFP ? cells are SMCs. In vein grafts created in RFP flox -GFP/Wnt1-Cre ? mice, GFP-positive cells were found in the neointima (Fig. 4e) . This suggests that SMCs from the common carotid artery (GFP ? ) were contributing to the formation of a neointima in the vein grafts. We also noted the presence of some RFP ? /GFP -cells in the neointima (Fig. 4e) . Double staining for GFP and SMA-a revealed that *44 % of GFP-positive cells were also positive for SMA-a (Fig. 4f, g ) while, approximately, *33 % of GFP negative neointima cells were SMA-a positive (Fig. 4f, g ). This suggested that these cells were not derived from the neighboring arterial SMCs and other sources (e.g., multipotent vascular stem cells, endothelial cells) could be involved in SMC accumulation in vein grafts. The presence of *10 % of GFP ? /SMA-a -cells in the neointima (Fig. 4f, g ) indicated that these cells were dedifferentiated SMCs that migrated from the neighboring artery. expression was determined by immunostaining. Results showed that Wnt1 was only expressed in the vagus nerve, and was absent from the neointima cells (Fig. 5a, upper  panel) . On the other hand, GFP-positive cells were found in the neointima (Fig. 5a , middle panel), suggesting that these GFP ? /Wnt1 -cells in the neointima were derived from SMCs in neighboring arteries. Double staining for Wnt1 and GFP further revealed that GFP-positive cells of the neointima did not express Wnt1 (Fig. 5b) . As a positive control, there was a strong Wnt1 expression colocalizing with GFP in the vagus nerve near the vein graft (Fig. 5c, upper panel) .
Bone marrow cells do not differentiate into SMCs in vein grafts
Because *50 % of neointima cells were not from neighboring arterial SMCs in the vein graft, they could be originating from the bone marrow. In order to explore the contribution of bone marrow cells, the vein grafts were placed in WT mice that had been transplanted with bone marrow cells isolated from RFP transgenic mice. After 1 month, we found bone marrow-derived RFP-positive cells in vein grafts, but these were not colocalized with SMA-a-positive cells (Fig. 6a) . We also found that SMA-a-positive cells were terminally differentiated SMCs; they were stained positively by the SMMHC and that none of them costained with RFP ? (data not shown). Instead the bone marrow-derived RFP cells co-stained with inflammatory cell markers such as CD45, Mac2, and CD3 (Fig. 6b-f ). These cells were mainly located between SMCs in the neointima and the adventitial area (Fig. 6b-e) . Few bone marrow-derived cells localized within the endothelium (Fig. 6b-e) . 
IGF-1R inhibitor suppresses SMC proliferation and neointima formation
The above experiments show that SMC migration from anastomosed arteries contributes to neointima formation in both the artery and vein grafts. To explore whether these migrated cells also proliferate, we performed artery and vein grafts and used BrdU to label the proliferating cells. Significant amount of BrdU-positive cells was found in the artery grafts (Fig. 7a) . Some BrdU-positive cells co-stained with SMA-a, indicating both migration-and proliferationmediated SMCs accumulation in neointima in artery (Fig. 7a) . Similar observations were confirmed in the vein grafts (Fig. 7b) . To examine if blocking IGF-1R inhibits SMC proliferation, quiescent SMCs were treated with IGF-1 (1 ng/ml) in the presence or absence of PPP, the IGF-1R inhibitor. BrdU incorporation was measured. The number of BrdU-positive cells was found to be increased in IGF-1 treated cells compared with results from control. PPP pretreatment blocked IGF-1-induced BrdU incorporation in SMCs (IGF-1, 9.69 ± 1.03 % vs. IGF-1/PPP, 3.63 ± 0.38, p \ 0.01, n = 3, Fig. 7c ). To further detect the effect of PPP on neointima formation, it was administered (i.p.) in mice with vein grafts and found to suppress the accumulation of the SMCs in the neointima (Fig. 7d, f) .
Discussion
Restenosis following neointima hyperplasia limits the success of bypass grafts or balloon angioplasty. We examined the source of cells in the neointima in models of artery or vein grafts. The artery graft is a model of events occurring after angioplasty. The mouse vein graft model is used to examine the pathogenesis of atherosclerosis in the vein as might occur in the aorta-coronary saphenous vein graft in human patients [17] , since it shares features similar to the vein graft in patients [11, 40] .
To identify the source of SMA-a-positive cells of the neointima in artery and vein grafts, we developed a strategy based on lessons from developmental biology. The transgenic mice that express Wnt1-Cre to label local SMCs arising from the common carotid artery were used in our experiments. In the artery-artery graft, [90 % of SMCs in the neointima were traced to the adjacent artery, the donor artery made a small contribution to neointima formation. In the vein graft model, *44 % of SMA-a-positive cells in the neointima originated from the neighboring arteries. This is the first report indicating that SMCs from neighboring vessels directly contribute to neointima formation in vein or artery grafts using Wnt1-Cre reporter mice.
The Wnt1 promoter efficiently targets the neural crestderived SMCs of the cardiac outflow tract composing the common carotid arteries. SMCs from other vasculature (e.g., veins) are not neural crest derived. Therefore, Wnt1-Cre/reporter transgenic mice were used to distinguish the source of SMCs of the cardiac outflow tract from other vasculatures. Several groups have used Wnt1-Cre/reporter mice to study the function of neural crest cells in the development of the cardiac outflow tract [19, 32] . In the current study, we used both LacZ-Stop flox /Wnt1-Cre ? and RFP flox -GFP/Wnt1-Cre ? mice to specifically label SMCs of the common carotid artery. These pre-labeled cells were found in both artery and vein grafts. Thus, the Wnt1-Cre/ reporter mice could be a tool to label and track SMCs in the aortic outflow during vascular remodeling. The origin of the neointima cells in vein graft models is controversial. Some reports conclude that neointima cells are exclusively composed of donor-originated cells in a venous graft [7] . Others report that bone marrow or ''graftextrinsic'' cells are predominant in the neointima [39] . In our experiments, we found that about 54 % of SMA-apositive cells in the neointima originated from the neighboring artery. Bone marrow cells did not contribute to the SMCs of the neointima in vein grafts as they only costained with the inflammatory markers, and were negative for the SMC markers, SMA-a or SMMHC. About 10 % of the neighboring artery-derived GFP ? cells in the neointima cells did not express the SMC markers (SMA-a) (Fig. 4e,  f) . This could represent dedifferentiated SMCs, since it has Fig. 7 IGF-1R inhibitor inhibits neointima formation. a Artery grafts were performed in WT mice. BrdU was applied i.p. for 7 days before the grafts were collected. Double immunostaining was performed to detect BrdU (green) and SMA-a (red) (n = 3). b Vein grafts were performed in WT mice. BrdU incorporation in SMCs in neointima was detected by immunostaining (n = 3). c SMCs were seeded onto a glass coverslip and kept in serum-free media for 24 h, cells were treated with IGF-1 (10 ng/ml) in the presence or absence of PPP (2 lM) for 24 h. The SMCs were incubated with BrdU for 3 h before fixation. BrdU-positive cells are shown in green; nuclei were counterstained with propidium iodide (red). Cell proliferation is expressed as the percentage of cells that were BrdU-positive as determined in five view fields. d, f Vein grafts were performed in WT mice. After 3 weeks of the surgery, mice were treated with PPP or solvent for 3 weeks. The vein grafts (1 month) were collected and stained with SMA-a. The layers of the SMCs were calculated (n = 4) been reported that the SMC cell phenotype is lost when contractile SMCs are dedifferentiated into synthetic SMCs [10] . Interestingly, the GFP -/SMA-a ? cells in the vein graft were not from the neighboring artery (Fig. 4e) , indicating that there are other sources, in the host or recipient vessels which can be differentiated into SMCs [18] . We speculate that SMCs present in the neointima of the vein graft might be derived from SMC progenitors [8, 38] , endothelial cells [4, 8] , or adventitial stem cells [18] .
In arterial remodeling, a long-standing concept in the field has been that the majority of neointima SMCs are derived from pre-existing media SMCs [21] . Different with this standing, we demonstrated that [90 % of SMCs in the neointima are from neighboring SMCs instead of the injured artery. Our results are consistent with recent findings, which showed that only flanking recipient SMCs contribute to vascular remodeling [12] . This observation is different with reports from several other groups who suggest that adventitial cells are the source of neointima cells in models of artery injury or vein grafts [27] [28] [29] [30] . In their report, the authors had used BrdU to label proliferating adventitial fibroblasts. Because BrdU labels all proliferating cells, it could not distinguish the cell origin of fibroblasts from medial SMCs in the neointima [29, 30] .
A recent report by Tang et al. [35] demonstrated that the multipotent vascular stem cells (MVSC) from the arterial wall contribute to neointima formation in the artery injury model. MVSC isolated from arteries and veins can be differentiated into several types of cells, including SMCs. Interestingly, MVSCs were also labeled in the common carotid artery in the Wnt1-Cre reporter mice [35] , suggesting that MVSCs could be involved in neointima formation in the vein or artery grafts. Because MVSCs are SMMHC negative [22, 35] , while we found that the GFPpositive cells in common carotid artery in Wnt1-Cre ? transgenic mice were SMMHC positive (Fig. 4c) , suggest that those GFP/SMMHC positive SMCs are precursors that contribute to neointima cells. We conclude that de-differentiation of SMCs in the anastomosed arteries are the major contributor for neointima formation. To specify the contribution of MVSCs to neotima formation, other strategies will be required to delineate the role of MVSCs. For example, a tamoxifen-inducible SMC-Cre reporter and/or SOX10-Cre reporter mice would be useful tools.
SMC proliferation plays an essential role in neointima formation. Our results also found that BrdU was incorporated in SMCs in the neointima. No BrdU-positive cells were found in the normal artery (data not shown). Thus, from Wnt1-Cre tracking and BrdU-labeling experiments, we conclude that both SMC migration and proliferation are involved in neointima formation. Among many factors that regulate SMC proliferation, growth factors (PDGF, TGFb1) play an important role in promoting SMC hyperplasia and neointima formation [15, 23] . Earlier, we have shown the suppression of neointima formation in the vein grafts of the knockout IGF-1R mice [5] . Consistent with this report, application of IGF-1R inhibitor, PPP, in mice significantly blocked SMC proliferation and neointima formation.
To summarize, we demonstrate that SMCs from the neighboring artery play an essential role in the composition of neointima cells in both the vein and artery grafts. These findings will guide the development of intervention methods, based on the migration and proliferation of SMCs in vascular remodeling, after angioplasty or coronary artery bypass surgery.
